Higher pretreatment PSA levels and older age in the definitive ExRT group than the RP group could be explained by the referral of these patients considerably to radiotherapy rather than surgery and shorter follow-up period in the RP group than the definitive ExRT group could be explained by the recently recognition of RP as an optional treatment in the context of multimodal treatment [3, 4] in high-risk PCa patients. The gene discussed is KLK3; the disease is posterior cortical atrophy.